Investigational Drug Information for Lucitanib
✉ Email this page to a colleague
What is the drug development status for Lucitanib?
Lucitanib is an investigational drug.
There have been 9 clinical trials for Lucitanib.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 14th 2019.
The most common disease conditions in clinical trials are Lung Neoplasms, Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Clovis Oncology, Inc., Bristol-Myers Squibb, and Institut de Recherches Internationales Servier.
There are forty US patents protecting this investigational drug and three hundred and fifty-six international patents.
Summary for Lucitanib
US Patents | 40 |
International Patents | 356 |
US Patent Applications | 179 |
WIPO Patent Applications | 140 |
Japanese Patent Applications | 47 |
Clinical Trial Progress | Phase 2 (2019-11-14) |
Vendors | 60 |
Recent Clinical Trials for Lucitanib
Title | Sponsor | Phase |
---|---|---|
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | Clovis Oncology, Inc. | Phase 1/Phase 2 |
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | Eli Lilly and Company | Phase 1/Phase 2 |
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | Exelixis | Phase 1/Phase 2 |
Clinical Trial Summary for Lucitanib
Top disease conditions for Lucitanib
Top clinical trial sponsors for Lucitanib
US Patents for Lucitanib
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Lucitanib | ⤷ Try a Trial | Bicyclic fused pyrimidine compounds as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
Lucitanib | ⤷ Try a Trial | Human anti-VEGFR-2/KDR antibodies | KADMON CORPORATION, LLC (New York, NY) | ⤷ Try a Trial |
Lucitanib | ⤷ Try a Trial | Pyrrolopyrimidine derivatives as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
Lucitanib | ⤷ Try a Trial | Rho kinase inhibitors | KADMON CORPORATION, LLC (New York, NY) | ⤷ Try a Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Lucitanib
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Lucitanib | World Intellectual Property Organization (WIPO) | WO2017027717 | 2035-08-12 | ⤷ Try a Trial |
Lucitanib | Canada | CA2926386 | 2032-10-05 | ⤷ Try a Trial |
Lucitanib | China | CN105007939 | 2032-10-05 | ⤷ Try a Trial |
Lucitanib | China | CN109160950 | 2032-10-05 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |